Applications Face Rejection As China FDA Starts ‘Intensive Review’
This article was originally published in The Pink Sheet Daily
Executive Summary
In a rare move, the China FDA has rejected 11 new drug applications from eight companies that were in its review queue, signaling more action to come as the agency ups punishments for clinical data forgery and prepares another intensive review campaign, its third in a decade.